| 蒋 荔,徐 鹏,吕志国,张冬梅,卢 靖,黄清霞,张艺缤,单慧毓,王 健.芪参地黄颗粒对实验性自身免疫性重症肌无力大鼠B细胞介导的免疫机制研究[J].,2022,(3):432-436 |
| 芪参地黄颗粒对实验性自身免疫性重症肌无力大鼠B细胞介导的免疫机制研究 |
| Study of Qishendihuang Granule on B Cell-Mediated Immune Mechanism of Experimental Autoimmune Myasthenia Gravis Rats |
| 投稿时间：2021-05-06 修订日期：2021-05-31 |
| DOI：10.13241/j.cnki.pmb.2022.03.007 |
| 中文关键词: 芪参地黄颗粒 实验性自身免疫性重症肌无力 免疫 B细胞 |
| 英文关键词: Qishendihuang granule Experimental autoimmune myasthenia gravis Immune B cells |
| 基金项目:吉林省科技发展计划项目（20190905005SF，20180311025YY）；吉林省中医药科技项目（2020164）；吉林省卫生健康技术创新项目（20191056，2019ZC004） |
|
| 摘要点击次数: 654 |
| 全文下载次数: 324 |
| 中文摘要: |
| 摘要 目的：探讨芪参地黄颗粒对实验性自身免疫性重症肌无力（EAMG）大鼠B细胞介导的免疫机制。方法：通过Rα97-116肽段和完全弗氏佐剂免疫，成功将30只Lewis大鼠构建EAMG模型，将EAMG大鼠随机分为模型组、芪参地黄颗粒低、中、高剂量组和阳性药组，每组6只。进一步观察大鼠体重及临床症状，检测血清中乙酰胆碱受体抗体（AChR-Ab）含量、脾脏组织CD19和CD27的蛋白表达、B淋巴细胞刺激因子（BAFF）、B细胞趋化因子CXC配体13（CXCL13）、C-X-C趋化因子受体5型（CXCR5） mRNA表达。结果：经给药治疗后芪参地黄颗粒低、中、高剂量组和阳性药组与模型组相比体重增加（P＜0.05），临床症状评分均下降（P＜0.05）。经给药治疗后，与模型组相比，芪参地黄颗粒低、中、高剂量组血清中AChR-Ab含量均降低（P<0.05），芪参地黄颗粒中、高剂量组脾脏组织CD27蛋白表达、CD19蛋白表达和BAFF mRNA表达降低（P＜0.05），芪参地黄颗粒高剂量组脾脏组织CXCL13和CXCR5 mRNA表达降低（P＜0.05），且芪参地黄颗粒中、高剂量组脾脏组织CD19蛋白表达较阳性药组下降（P＜0.05）。结论：芪参地黄颗粒通过降低EAMG大鼠CD19和CD27蛋白、BAFF、CXCL13和CXCR5 mRNA的表达，减少B细胞的分化增殖，抑制B细胞产生AChR-Ab，减少对乙酰胆碱受体的破坏，使EAMG大鼠体重增加，临床症状得到改善。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the immune mechanism of Qishendihuang granule on B cell-mediated of experimental autoimmune myasthenia gravis (EAMG) rats. Methods: By immunizing with Rα97-116 peptide and complete Freund's adjuvant, 30 Lewis rats were successfully constructed EAMG model. EAMG rats were randomly divided into model group, Qishendihuang granule low, medium and high dose groups and positive drug group, 6 rats in each group. The weight and clinical symptoms of the rats were further observed, and the serum acetylcholine receptor antibody (AChR-Ab) content, the protein expression of CD19 and CD27 in the spleen and the expression of B lymphocyte stimulating factor (BAFF), B cell chemokine CXC ligand 13 (CXCL13) and C-X-C chemokine receptor type 5 (CXCR5) mRNA were detected. Results: After administration of drug treatment, the weight of low, medium and high dose groups and positive drug group of Qishendihuang granule increased compared with that in the model group(P<0.05), and the clinical symptom scores all decreased(P<0.05). After administration of drug treatment, compared with the model group, the serum AChR-Ab content of the Qishendihuang granule low, medium and high dose groups all decreased(P＜0.05), and the expression of CD27 protein, CD19 protein and BAFF mRNA in the spleen of Qishendihuang granule medium and high dose groups decreased (P＜0.05), and the expression of CXCL13 and CXCR5 mRNA in the spleen of Qishendihuang granule high dose group decreased(P＜0.05), moreover, the expression of CD19 protein in spleen tissues of Qishendihuang granule medium and high dose groups decreased compared with that of positive drug group(P＜0.05). Conclusion: Qishendihuang granule can reduce the expression of D19 and CD27, BAFF, CXCL13 and CXCR5 in EAMG rats, reduce the differentiation and proliferation of B cells, inhibit the production of AChR-Ab by B cells, reduce the damage to acetylcholine receptor, and increase the weight of EAMG rats, and improve the clinical symptoms. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
